FreeTender
Accepting bidsgrantUnited States

Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)

Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities

Verify & apply on the official portal →
Published
1 Sept 2026
Closes
9 Oct 2028, 23:59 UTC
Reference
RFA-AI-27-014
Location
United States
Sector
Healthcare & Pharma

At a glance

National Institutes of Health in United States has published a funding call in healthcare & pharma: “Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)”. Submissions close on 9 October 2028, 696 days from today. Quote reference RFA-AI-27-014 in any correspondence with the buyer. FreeTender has recorded 459 notices from this buyer since 2023, 368 of them currently open. There are 385 open healthcare & pharma notices in United States on FreeTender. Bids are submitted to the buyer through Grants.gov — US federal funding opportunities, not through FreeTender.

Key requirements

Taken from the notice by FreeTender. The tender document on the official portal is binding — check it, and any corrigendum, before you bid.

To bid on Grants.gov (US federal)

Applicants need a UEI from SAM.gov and a Grants.gov account registered to their organisation; allow several weeks for registration.

Details

The purpose of this notice of funding opportunity (NOFO) is to support research that advances understanding of the natural history of radiation or chemical exposures; develops relevant injury models; identifies and validates diagnostic tools, biomarkers, or triage technologies; and supports the development of effective medical countermeasures (MCMs) to mitigate or treat acute and/or delayed injuries resulting from radiological/nuclear or chemical public health emergencies. Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

CFDA number(s): 93.233

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.

Context for bidders

We hold 459 notices from National Institutes of Health, going back to May 2023 — 368 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 385 open Healthcare & Pharma tenders in United States. This one closes in 696 days.

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
Common bidding mistakes to avoid →Writing a winning proposal

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →